[Summary] A landmark systematic review published in Frontiers in Nutrition in April 2026 has confirmed the significant efficacy of Dihydromyricetin (DHM) in addressing Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). As the global liver health supplement market scales toward $1.56 billion, DHM is rapidly evolving from a niche "hangover recovery" aid into a cornerstone of long-term metabolic health formulations.
According to the comprehensive meta-analysis published on April 7, 2026, researchers analyzed 14 controlled studies following the PRISMA 2020 framework. The findings provide overwhelming statistical evidence for DHM’s role in regulating hepatic lipid metabolism.
· Hepatic Repair: Significant reduction in liver injury biomarkers, including ALT (SMD = -3.79) and AST (SMD = -2.97).
· Lipid Modulation: Substantial decrease in hepatic triglycerides (p < 0.001) and fasting insulin levels.
· AMPK Activation: The study confirms that DHM significantly increases the pAMPK/AMPK ratio (SMD = 6.07), activating the essential pathway for cellular energy homeostasis and lipid oxidation.
Formulator’s Insight: The research highlights that sustained daily intervention (8+ weeks) yields the most stable results. This shift is driving the demand for High-Purity Dihydromyricetin (DHM) Raw Materials in daily wellness capsules rather than occasional-use products.
Market data for the first half of 2026 indicates a 35% surge in the inclusion of high-purity DHM within daily wellness formulas. Global consumer behavior is pivoting toward proactive maintenance:
1. Daily Liver Detox: Rebranding DHM as a core hepatoprotective ingredient for consumers managing high-fat diets or sedentary lifestyles.
2. Functional RTD Beverages: A surge in demand for recovery drinks featuring nano-emulsified DHM for enhanced stability in North American and European markets.
3. Synergistic Formulations: Combining DHM Extract with N-Acetyl Cysteine (NAC) and Milk Thistle for comprehensive cellular support.
In 2026, the DHM supply chain is no longer defined by price, but by technical specifications. Leading brands now vet suppliers based on rigorous criteria:
With the rising global prevalence of MASLD and the progress of Phase I Clinical Trials (NCT05623501), DHM is projected to see explosive growth over the next 18 months. For brands looking to lead the market, securing a high-quality supply chain now is essential for successful product launches in late 2026.
Shanghai Aidu Biotechnology Co., Ltd is a premier global developer and industrial-scale manufacturer of Dihydromyricetin (DHM). We provide:
· Standardized High-Purity Ingredients: Produced under strict cGMP and ISO standards.
· Comprehensive Technical Support: Detailed COA, specifications, and formulation guidance.
· Customized Solutions: Specialized DHM grades for capsules, tablets, and functional beverages.
Contact our expert team for samples and quotes: Contact Us
Visit our Product Center: Dihydromyricetin (DHM) Series